ArticleScientific reports2015
Formulation Strategy for the Delivery of Cyclosporine A: Comparison of Two Polymeric Nanospheres.
Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Comparing the efficacy of nanocarriers for cutaneous and follicular delivery of poorly water-soluble molecules: A case study with ciclosporin A.International journal of pharmaceutics: X · 2026Article
- In Vitro Evaluation of Necrostatin-1 Microparticles for Limiting Stress-induced Cell Death and Preserving Islet Function.Transplantation direct · 2026Article
- Potential and challenges in application of physiologically based pharmacokinetic modeling in predicting diarrheal disease impact on oral drug pharmacokinetics.Drug metabolism and disposition: the biological fate of chemicals · 2025Review
- Darunavir Nanoformulation Suppresses HIV Pathogenesis in Macrophages and Improves Drug Delivery to the Brain in Mice.Pharmaceutics · 2024Article
- Rapidly Dissolving Trans-scleral Microneedles for Intraocular Delivery of Cyclosporine A.AAPS PharmSciTech · 2024Article
- Improve BBB Penetration and Cytotoxicity of Palbociclib in U87-MG Glioblastoma Cells Delivered by Dual Peptide Functionalized Nanoparticles.Pharmaceutics · 2023Article
- Long-Term Survival and Induction of Operational Tolerance to Murine Islet Allografts by Co-Transplanting Cyclosporine A Microparticles and CTLA4-Ig.Pharmaceutics · 2023Article
- A comprehensive review on possibilities of treating psoriasis using dermal cyclosporine.Drug delivery and translational research · 2022Review
- Production of α-Tocopherol-Chitosan Nanoparticles by Membrane Emulsification.Molecules (Basel, Switzerland) · 2022Article
- Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies.Drug delivery and translational research · 2022Article
- New Nanoparticle Formulation for Cyclosporin A: In Vitro Assessment.Pharmaceutics · 2021Article
- Drug-Integrating Amphiphilic Nanomaterial Assemblies: 1. Spatiotemporal control of cyclosporine delivery and activity using nanomicelles and nanofibrils.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Supramolecular and Macromolecular Matrix Nanocarriers for Drug Delivery in Inflammation-Associated Skin Diseases.Pharmaceutics · 2020Review
- Hexosomes as Efficient Platforms for Possible Fluoxetine Hydrochloride Repurposing with Improved Cytotoxicity against HepG2 Cells.ACS omega · 2020Article
- Opportunities for biomaterials to address the challenges of COVID-19.Journal of biomedical materials research. Part A · 2020Review
- Freeze-Dried SoftisanNanomaterials (Basel, Switzerland) · 2020Article
- Assembling Surfactants-Mucoadhesive Polymer Nanomicelles (ASMP-Nano) for Ocular Delivery of Cyclosporine-A.Pharmaceutics · 2020Article
- Topical Delivery of Immunosuppression to Prolong Xenogeneic and Allogeneic Split-Thickness Skin Graft Survival.Journal of burn care & research : official publication of the American Burn Association · 2018Article
- Flash nanoprecipitation permits versatile assembly and loading of polymeric bicontinuous cubic nanospheres.Nanoscale · 2018Article
- Nanospheres with a smectic hydrophobic core and an amorphous PEG hydrophilic shell: structural changes and implications for drug delivery.Soft matter · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
A wide range of nanoparticles has been explored for the delivery of highly hydrophobic drugs, but very few publications provide comparative data of the performance of different nanoparticles. To address this need, this publication compares poly(lactic-co-glycolic acid) (PLGA) nanoparticles and nanospheres made from tyrosine-derived tri-block copolymers (termed TyroSpheres) for their respective performance as carriers for cyclosporine A (CSA). Using previously reported data on PLGA, we followed similar experimental protocols to evaluate the in vitro characteristics of TyroSpheres. Although there are some similarities between the two particle systems for the delivery of CSA, such as effective encapsulation and epidermal skin penetration, several differences were notable. First, the methods of preparation were different, i.e., self-assembly and emulsion-diffusion-evaporation process for TyroSpheres and PLGA, respectively. Second, TyroSpheres provided 7-day diffusion-controlled release, whereas PLGA nanoparticles provided >21-day erosion-controlled release. Third, the size of TyroSpheres was measured to be ~60-70 nm irrespective of drug loading, whereas the size of PLGA nanoparticles (~100-250 nm) was dependent on drug loading and the method of preparation. Overall, this publication provides a direct comparison between two different types of nanoparticles and illuminates the respective advantages and disadvantages, using CSA as a model for the release of highly hydrophobic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.